Earnings call transcript: Sallie Mae misses Q2 2026 profit view as shares fall

Sallie Mae (SLM) reported Q2 2026 adjusted/GAAP EPS of $0.29 vs. $0.45 expected and revenue of $401M vs. $414.98M, with the EPS miss ($-0.16, -35.6%) driving a stock decline—down 4.12% in regular trading to $24.18 and another 2.11% after hours to $23.67. Net interest margin fell to 4.75% and net charge-offs rose to $113M ($94M prior year), though management said Q2 likely marked the low point with margin expected to improve in 2H toward ~5%. The company narrowed net charge-off guidance to $365M–$385M (raising the low end by $20M) while continuing capital returns, including a completed 13M share repurchase year to date.

Analysis

This read is more about earnings quality than demand destruction. The market is punishing the quarter because profits were pulled down by a mix of temporary liquidity drag, recovery-channel disruption, and one-off growth spend, but the larger mechanism is that SLM is deliberately trading current-year recoveries for tighter control of post-default economics. That is a near-term EPS headwind, yet it can improve loss realization and borrower optics over 6-18 months if internal recoveries truly outperform outsourced sales.

The second-order winner is the capital-light partnership model. KKR benefits from a growing fee stream without taking balance-sheet duration or charge-off risk, while SLM is converting part of the franchise from spread income to recurring fee income; that should support multiple stability if execution holds. The risk is that investors are overestimating how quickly peak-season originations and buybacks offset the recovery and expense drag: if the loan mix skews more toward graduate products with lower realized yield or slower disbursement conversion, the NIM rebound may be shallower than management implies.

Contrarianly, the consensus may be focusing too much on the EPS miss and not enough on the share count reduction plus medium-term operating leverage. The real falsifier is not one bad quarter, but whether Q3/Q4 show NIM moving back toward 5%, charge-off guidance staying contained, and fee revenue scaling. If that sequence fails, the low-teens ROE narrative compresses quickly and the stock can re-rate lower despite the cheap headline multiple.

Key Decisions for Investors

• Tactically buy SLM only on post-earnings weakness if it holds above the low-$23s; base case is a 10-15% rebound into the Q3 update if NIM inflects and buybacks continue. Use a hard risk limit on any close below the post-print low as confirmation that the recovery thesis is failing.
• Consider a Jan-2027 SLM 25/30 call spread for asymmetric exposure to the peak-season NIM rebound and renewed capital returns; this expresses upside without paying full equity beta for a thesis that needs 2-3 quarters to prove out.
• Add KKR as a relative winner on any SLM-related selloff: the partnership model improves fee visibility with limited credit exposure. Use it as a lower-volatility way to own the monetization of SLM-originated assets while avoiding balance-sheet noise.
• Set a watch alert for SLM Q3 indicators: NIM at or above ~4.9%, charge-offs within the narrowed range, and fee-based revenue growth. If those do not show up, exit the long and reassess for a lower multiple.
• If you want to fade the optimism, short SLM against a basket of capital-returning financials only after the next print if margin recovery stalls; the trade is only attractive if the market is still pricing in a full recovery by year-end that the fundamentals do not yet support.